118 related articles for article (PubMed ID: 26257279)
1. Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome.
Weyand AC; Yanik GA; Bailey NG; Wu YM; Mody RJ; Castle VP
Pediatr Blood Cancer; 2016 Jan; 63(1):164-7. PubMed ID: 26257279
[TBL] [Abstract][Full Text] [Related]
2. Management of Hypereosinophilic Syndromes.
Roufosse F
Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
[TBL] [Abstract][Full Text] [Related]
3. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.
Khoury P; Desmond R; Pabon A; Holland-Thomas N; Ware JM; Arthur DC; Kurlander R; Fay MP; Maric I; Klion AD
Allergy; 2016 Jun; 71(6):803-10. PubMed ID: 26797802
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?
Helbig G
Eur J Intern Med; 2016 Jul; 32():e19-20. PubMed ID: 26968968
[No Abstract] [Full Text] [Related]
5. Exquisite response to imatinib mesylate in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome: a 12-year experience of the Polish Hypereosinophilic Syndrome Study Group.
Helbig G; Lewandowski K; Świderska A; Rodzaj M; Seferyńska I; Gajkowska-Kulik J
Pol Arch Intern Med; 2020 Mar; 130(3):255-257. PubMed ID: 32125294
[No Abstract] [Full Text] [Related]
6. Hypereosinophilia and severe bone disease in an African child: an unexpected diagnosis.
Bota S; Alves P; Constantino C; Maia R
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31036733
[TBL] [Abstract][Full Text] [Related]
7. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
[TBL] [Abstract][Full Text] [Related]
8. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
[TBL] [Abstract][Full Text] [Related]
9. Cough in hypereosinophilic syndrome: case report and literature review.
Xie J; Zhang J; Zhang X; Zhang Q; Chung KF; Wang C; Lai K
BMC Pulm Med; 2020 Apr; 20(1):90. PubMed ID: 32293378
[TBL] [Abstract][Full Text] [Related]
10. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
11. Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.
Walz C; Curtis C; Schnittger S; Schultheis B; Metzgeroth G; Schoch C; Lengfelder E; Erben P; Müller MC; Haferlach T; Hochhaus A; Hehlmann R; Cross NC; Reiter A
Genes Chromosomes Cancer; 2006 Oct; 45(10):950-6. PubMed ID: 16845659
[TBL] [Abstract][Full Text] [Related]
12. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia.
Score J; Curtis C; Waghorn K; Stalder M; Jotterand M; Grand FH; Cross NC
Leukemia; 2006 May; 20(5):827-32. PubMed ID: 16498388
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment with imatinib of lymphomatoid papulosis associated with myeloproliferative hypereosinophilic syndrome with PDGFRA rearrangement.
Torres-Navarro I; Navarro-Mira MÁ; de Unamuno-Bustos B; Botella-Estrada R
J Dtsch Dermatol Ges; 2020 Apr; 18(4):378-380. PubMed ID: 32291914
[No Abstract] [Full Text] [Related]
14. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.
Roche-Lestienne C; Lepers S; Soenen-Cornu V; Kahn JE; Laï JL; Hachulla E; Drupt F; Demarty AL; Roumier AS; Gardembas M; Dib M; Philippe N; Cambier N; Barete S; Libersa C; Bletry O; Hatron PY; Quesnel B; Rose C; Maloum K; Blanchet O; Fenaux P; Prin L; Preudhomme C
Leukemia; 2005 May; 19(5):792-8. PubMed ID: 15772698
[TBL] [Abstract][Full Text] [Related]
16. Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
Iurlo A; Cattaneo D; Gianelli U
Expert Rev Hematol; 2019 Dec; 12(12):1077-1088. PubMed ID: 31588817
[No Abstract] [Full Text] [Related]
17. Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib.
Garcia-Alvarez A; Sitges M; Garcia-Albeniz X; Sionis A; Loma-Osorio P; Bosch X
Int J Cardiol; 2010 Mar; 139(2):e29-31. PubMed ID: 19056137
[TBL] [Abstract][Full Text] [Related]
18. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.
Cross NC; Reiter A
Acta Haematol; 2008; 119(4):199-206. PubMed ID: 18566537
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
